Clinical trial · Interventional
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD). The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation. Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment. The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Obstructive Pulmonary Disease | — | UNRESOLVED | — |
| Immune Dysregulation | — | UNRESOLVED | — |
| Immunotherapy Resistance | — | UNRESOLVED | — |
| Lung Cancer (Diagnosis) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
| Sarcoidosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Peripheral Blood Collection for Immune Profiling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- OTHER
- label
- Patients with precancerous lung lesions
- description
- Patients with precancerous lung lesions under clinical monitoring
- interventionNames
- Other: Peripheral Blood Collection for Immune Profiling
- type
- ACTIVE_COMPARATOR
- label
- Lung cancer
- description
- Patients with a diagnosis of lung cancer (all stages)
- interventionNames
- Other: Peripheral Blood Collection for Immune Profiling
- type
- OTHER
- label
- Sarcoidosis and COPD
- description
- Patients with chronic inflammatory lung diseases
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of lung cancer * Presence of precancerous lung lesions * Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment * Control group: individuals without known lung disease * Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD) * Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected Exclusion Criteria: * Systemic corticosteroid therapy \> 10 mg/day prednisone (or equivalent) * Acute infection at the time of inclusion * Refusal or inability to provide informed consent (or assent, when applicable) * Chronic inflammatory lung disease currently treated with immunosuppressive therapy
References
Publications (5)
- RESULTDesai A, Prasad V. Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions? J Gen Intern Med. 2021 Oct;36(10):3202-3204. doi: 10.1007/s11606-021-06806-5. Epub 2021 Apr 26. No abstract available. PMID 33904047
- RESULTHaslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535. PMID 31050774
- RESULTDelhez N, Aboubakar Nana F, Houbion C, Bayard A, Bruger A, Vanhaver C, Brandau S, van der Bruggen P, Hirsch T. Deciphering neutrophil heterogeneity in human blood and tumors: Methods for isolating neutrophils and assessing their effect on T-cell proliferation. Methods Cell Biol. 2025;191:151-196. doi: 10.1016/bs.mcb.2024.10.010. Epub 2024 Nov 25. PMID 39824555
- RESULTBruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2019 Apr;68(4):631-644. doi: 10.1007/s00262-018-2170-8. Epub 2018 May 21. PMID 29785656
- RESULTVanhaver C, Aboubakar Nana F, Delhez N, Luyckx M, Hirsch T, Bayard A, Houbion C, Dauguet N, Brochier A, van der Bruggen P, Bruger AM. Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype. Life Sci Alliance. 2023 Nov 6;7(1):e202302332. doi: 10.26508/lsa.202302332. Print 2024 Jan. PMID 37931958